Henriksson Anna, Strandberg Emelie, Stenling Andreas, Mazzoni Anne-Sophie, Sjövall Katarina, Börjeson Sussanne, Raastad Truls, Demmelmaier Ingrid, Berntsen Sveinung, Nordin Karin
Department of Public Health and Caring Sciences, Uppsala University, Uppsala, Sweden.
Department of Sport Science and Physical Education, University of Agder, Kristiansand, Norway.
BMC Sports Sci Med Rehabil. 2023 Jan 19;15(1):8. doi: 10.1186/s13102-023-00617-3.
Resistance exercise has a beneficial impact on physical function for patients receiving oncological treatment. However, there is an inter-individual variation in the response to exercise and the tolerability to high-intensity exercise. Identifying potential moderating factors, such as inflammation and treatment type, for changes in muscle strength is important to improve the effectiveness of exercise programs. Therefore, we aimed to investigate if inflammation and type of oncological treatment moderate the effects of exercise intensity (high vs. low-moderate) on muscular strength changes in patients with breast (BRCA) or prostate cancer (PRCA).
Participants with BRCA (n = 286) and PRCA (n = 65) from the Physical training and Cancer study (Phys-Can) were included in the present study. Participants performed a combined resistance- and endurance exercise program during six months, at either high or low-moderate intensity. Separate regression models were estimated for each cancer type, with and without interaction terms. Moderators included in the models were treatment type (i.e., neo/adjuvant chemotherapy-yes/no for BRCA, adjuvant androgen deprivation therapy (ADT)-yes/no for PRCA)), and inflammation (interleukin 6 (IL6) and tumor necrosis factor-alpha (TNFα)) at follow-up.
For BRCA, neither IL6 (b = 2.469, 95% CI [- 7.614, 12.552]) nor TNFα (b = 0.036, 95% CI [- 6.345, 6.418]) levels moderated the effect of exercise intensity on muscle strength change. The same was observed for chemotherapy treatment (b = 4.893, 95% CI [- 2.938, 12.724]). Similarly, for PRCA, the effect of exercise intensity on muscle strength change was not moderated by IL6 (b = - 1.423, 95% CI [- 17.894, 15.048]) and TNFα (b = - 1.905, 95% CI [- 8.542, 4.732]) levels, nor by ADT (b = - 0.180, 95% CI [- 11.201, 10.841]).
The effect of exercise intensity on muscle strength is not moderated by TNFα, IL6, neo/adjuvant chemotherapy, or ADT, and therefore cannot explain any intra-variation of training response regarding exercise intensity (e.g., strength gain) for BRCA or PRCA in this setting.
ClinicalTrials.gov NCT02473003.
抗阻运动对接受肿瘤治疗的患者的身体功能有有益影响。然而，运动反应和对高强度运动的耐受性存在个体差异。识别潜在的调节因素，如炎症和治疗类型，对于肌肉力量变化很重要，有助于提高运动计划的有效性。因此，我们旨在研究炎症和肿瘤治疗类型是否会调节运动强度（高与低-中度）对乳腺癌（BRCA）或前列腺癌（PRCA）患者肌肉力量变化的影响。
本研究纳入了来自体育锻炼与癌症研究（Phys-Can）的BRCA患者（n = 286）和PRCA患者（n = 65）。参与者在六个月内进行了一项结合抗阻和耐力的运动计划，运动强度为高或低-中度。针对每种癌症类型，分别估计了有无交互项的回归模型。模型中纳入的调节因素包括治疗类型（即BRCA的新辅助/辅助化疗-是/否，PRCA的辅助雄激素剥夺治疗（ADT）-是/否），以及随访时的炎症（白细胞介素6（IL6）和肿瘤坏死因子-α（TNFα））。
对于BRCA，IL6（b = 2.469，95%CI[-7.614，12.552]）和TNFα（b = 0.036，95%CI[-6.345，6.418]）水平均未调节运动强度对肌肉力量变化的影响。化疗治疗的情况也是如此（b = 4.893，95%CI[-2.938，12.724]）。同样，对于PRCA，IL6（b = -1.423，95%CI[-17.894，15.048]）和TNFα（b = -1.905，95%CI[-8.542，4.732]）水平以及ADT（b = -0.180，95%CI[-11.201，10.841]）均未调节运动强度对肌肉力量变化的影响。
TNFα、IL6、新辅助/辅助化疗或ADT均未调节运动强度对肌肉力量的影响，因此无法解释在这种情况下BRCA或PRCA患者运动强度（如力量增加）的训练反应的个体差异。
ClinicalTrials.gov NCT02473003。
